CME Group (NASDAQ:CME) posted its quarterly earnings data on Wednesday. The financial services provider reported $1.63 EPS for the quarter, topping the Zacks’ consensus estimate of $1.62 by $0.01, MarketWatch Earnings reports. CME Group had a return on equity of 9.93% and a net margin of 46.39%. The company had revenue of $1.18 billion for the quarter, compared to the consensus estimate of $1.20 billion. During the same quarter in the previous year, the business earned $1.76 EPS. The company’s quarterly revenue was down 7.1% compared to the same quarter last year.

NASDAQ:CME traded up $3.08 during trading hours on Friday, hitting $166.18. 1,845,262 shares of the company’s stock traded hands, compared to its average volume of 1,553,448. The firm has a market cap of $59.59 billion, a P/E ratio of 25.06, a P/E/G ratio of 4.93 and a beta of 0.30. CME Group has a twelve month low of $131.80 and a twelve month high of $225.36. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.01 and a current ratio of 1.02. The stock’s fifty day moving average price is $169.99 and its two-hundred day moving average price is $186.20.

In other CME Group news, Director Timothy S. Bitsberger sold 600 shares of the business’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $191.32, for a total value of $114,792.00. Following the transaction, the director now owns 9,927 shares in the company, valued at $1,899,233.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director William R. Shepard bought 1,229 shares of the stock in a transaction on Thursday, June 11th. The stock was purchased at an average price of $178.10 per share, for a total transaction of $218,884.90. Following the purchase, the director now directly owns 2,000 shares of the company’s stock, valued at $356,200. The disclosure for this purchase can be found here. 1.20% of the stock is currently owned by insiders.

A number of analysts have recently commented on the company. BidaskClub downgraded CME Group from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Oppenheimer reaffirmed a “buy” rating on shares of CME Group in a research report on Wednesday. Barclays reaffirmed a “buy” rating and set a $200.00 target price on shares of CME Group in a research report on Tuesday, April 14th. UBS Group boosted their target price on CME Group from $222.00 to $225.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Finally, Credit Suisse Group cut their target price on CME Group from $190.00 to $183.00 and set a “neutral” rating on the stock in a research report on Tuesday, June 23rd. Four research analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $187.88.

CME Group Company Profile

CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals, as well as fixed income products.

See Also: How can investors benefit from after-hours trading?

Earnings History for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.